| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GOLPH2 |
| Uniprot No | Q8NBJ4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-401aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSSSRSVDL QTRIMELEGR VRRAAAERGA VELKKNEFQG ELEKQREQLD KIQSSHNFQL ESVNKLYQDE KAVLVNNITT GERLIRVLQD QLKTLQRNYG RLQQDVLQFQ KNQTNLERKF SYDLSQCINQ MKEVKEQCEE RIEEVTKKGN EAVASRDLSE NNDQRQQLQA LSEPQPRLQA AGLPHTEVPQ GKGNVLGNSK SQTPAPSSEV VLDSKRQVEK EETNEIQVVN EEPQRDRLPQ EPGREQVVED RPVGGRGFGG AGELGQTPQV QAALSVSQEN PEMEGPERDQ LVIPDGQEEE QEAAGEGRNQ QKLRGEDDYN MDENEAESET DKQAALAGND RNIDVFNVED QKRDTINLLD QREKRNHTL |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GOLPH2重组蛋白的3篇参考文献示例(文献标题及摘要为虚构模拟内容，仅供参考格式)：
1. **文献名称**: *Recombinant GOLPH2 Protein Expression and Its Role in Hepatocellular Carcinoma Diagnosis*
**作者**: Zhang L, et al.
**摘要**: 研究通过大肠杆菌系统表达重组GOLPH2蛋白，验证其在肝癌患者血清中的高表达水平，提出其作为肝癌血清标志物的潜在价值。
2. **文献名称**: *Structural Characterization of Recombinant GOLPH2 and Its Interaction with Cellular Membranes*
**作者**: Schmidt M, et al.
**摘要**: 利用哺乳动物细胞表达系统获得重组GOLPH2蛋白，解析其N端结构域与高尔基体膜结合的分子机制，揭示其在细胞分泌途径中的作用。
3. **文献名称**: *GOLPH2 Recombinant Protein as a Novel Biomarker for Prostate Cancer: A Comparative Study*
**作者**: Kim S, et al.
**摘要**: 通过真核表达纯化重组GOLPH2蛋白，比较其在前列腺癌组织与正常组织中的差异表达，证实其诊断敏感度优于传统标志物PSA。
如需真实文献，建议通过PubMed或Google Scholar检索关键词 "GOLPH2 recombinant protein" 或 "GOLM1 recombinant"。
GOLPH2 (Golgi phosphoprotein 2), also known as GOLM1 or GP73. is a type II transmembrane protein predominantly localized in the Golgi apparatus. It consists of a short N-terminal cytoplasmic domain, a transmembrane region, and a large C-terminal luminal domain. First identified in the context of liver diseases, GOLPH2 is synthesized in epithelial cells, with elevated expression observed in hepatocytes during pathological conditions such as hepatocellular carcinoma (HCC), viral hepatitis, and non-alcoholic fatty liver disease. Under normal physiological conditions, its expression is low in healthy liver tissue but increases significantly upon cellular stress or injury.
Functionally, GOLPH2 is implicated in Golgi structure maintenance, protein trafficking, and secretory pathways. It interacts with components of the vesicular transport machinery and may modulate immune responses. Recent studies suggest its involvement in cancer progression, particularly in promoting cell proliferation, metastasis, and epithelial-mesenchymal transition (EMT) through pathways like TGF-β and Wnt/β-catenin signaling. Its overexpression in malignancies, including prostate, lung, and colorectal cancers, has drawn attention as a potential biomarker.
Recombinant GOLPH2 protein, produced via bacterial or mammalian expression systems, retains the antigenic epitopes of native GOLPH2. It is commonly engineered with tags (e.g., His-tag) for purification and detection. This tool enables researchers to study GOLPH2’s biological roles, develop diagnostic assays (e.g., ELISA), and generate antibodies for clinical applications. Notably, serum GOLPH2 levels are being explored as a non-invasive biomarker for early HCC detection, complementing traditional markers like alpha-fetoprotein (AFP). Its diagnostic utility extends to distinguishing liver pathologies and monitoring treatment responses, highlighting its translational relevance in precision medicine.
×
